



# Progress in Drug Research

**Vol. 51**

Edited by Ernst Jucker, Basel

Board of Advisors

Joseph M. Colacino

Vera M. Kolb

J. Mark Treherne

Authors

Shijun Ren and Eric J. Lien

Nicholas C. Turner and John C. Clapham

Laszlo Prokai

Ravenska T.E. Wagey and Charles Krieger

Vera M. Kolb

Kirk W. Johnson, Lee A. Phebus and

Marlene L. Cohen

Barry A. Kenny, Mark Bushfield,

David J. Parry-Smith, Simon Fogarty

and J. Mark Treherne

## Editor

Dr. E. Jucker  
Steinweg 28  
CH-4107 Ettingen  
Switzerland  
e-mail: jucker.pdr@bluewin.ch

Visit our PDR homepage: <http://www.birkhauser/books/biosc/pdr>

ISBN 978-3-0348-9798-3    ISBN 978-3-0348-8845-5 (eBook)  
DOI 10.1007/978-3-0348-8845-5

The Publisher and Editor cannot assume any legal responsibility for information on drug dosage and administration contained in this publication. The respective user must check its accuracy by consulting other sources of reference in each individual case.

The use of registered names, trademarks etc. in this publication, even if not identified as such, does not imply that they are exempt from the relevant protective laws and regulations or free for general use.

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, re-use of illustrations, recitation, broadcasting, reproduction on microfilms or in other ways, and storage in data banks. For any kind of use permission of the copyright owner must be obtained.

© 1998 Springer Basel AG  
Originally published by Birkhäuser Verlag in 1998

Printed on acid-free paper produced from chlorine-free pulp. TCF  
Cover design and layout: Gröflin Graphic Design, Basel

# Contents

<b>Development of HIV protease inhibitors: A survey</b> .....	1
By Shijun Ren and Eric J. Lien	
<b>Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: Current status and therapeutic possibilities</b> .....	33
By Nicholas C. Turner and John C. Clapham	
<b>Peptide drug delivery into the central nervous system</b> .....	95
By Laszlo Prokai	
<b>Abnormalities of protein kinases in neurodegenerative diseases</b> .....	133
By Ravenska T.E. Wagey and Charles Krieger	
<b>Biomimicry as a basis for drug discovery</b> .....	185
By Vera M. Kolb	
<b>Serotonin in migraine: Theories, animal models and emerging therapies</b> .....	219
By Kirk W. Johnson, Lee A. Phebus and Marlene L. Cohen	
<b>The application of high-throughput screening to novel lead discovery</b> .....	245
By Barry A. Kenny, Mark Bushfield, David J. Parry-Smith, Simon Fogarty and J. Mark Treherne	
<b>Index Vol. 51</b> .....	271
<b>Index of titles, Vol. 1–51</b> .....	279
<b>Author and paper index, Vol. 1–51</b> .....	293

## Foreword by the Editor

Volume 51 of *Progress in Drug Research* contains seven reviews and the various indexes which facilitate the use of these monographs and also help to establish PDR as an encyclopedic source of information in the complex field of drug research. The articles in this volume, all written by experts in the respective fields of research, deal with the development of HIV protease inhibitors as antiviral agents against HIV, with insulin resistance and non-insulin-dependent diabetes, with peptide drug delivery into the central nervous system, emphasising their potential importance as novel neuropharmaceuticals, with abnormalities of protein kinases in neurodegenerative diseases, with biomimicry as a basis for drug discovery, with serotonin in migraine including a review on emerging therapies and, finally, with the application of high-throughput screening to novel lead discovery.

All these review articles contain extensive bibliographies, thus enabling the interested reader to have easy access to theoretical literature.

The *Progress in Drug Research* book series was founded 40 years ago to help disseminate information on the vast and fast growing domain of drug research. For the individual scientist it has become increasingly difficult to retain an overview of the enormous amount of information available, and PDR enables the reader to keep abreast of the latest developments and trends. This goal has remained until today, and the Editor is happy to say that the Publishers decided to modernise the layout of the monographs and to establish an Internet homepage with the relevant data of all 485 reviews published so far. In order to include the latest scientific findings and methods, I suggested to establish a Board of Advisors to help the Editor find the best-suited authors engaged in the newest fields of research, thus helping to keep this series up-to-date with the progress in drug research. I hope that our readers will appreciate these changes and efforts.

In the 40 years of the existence of PDR, the Editor has enjoyed much appreciated help and advice from the authors, the readers, many colleagues and, last but not least, from the reviewers. To all of them I would like to express my gratitude. In addition, I would like to extend my thanks to Birkhäuser Publishing and, in particular to Ms. Janine Kern and Mssrs. Eduard Mazenauer, Ruedi Jappert and Bernd Luchner who established the complex homepage for PDR on the Internet. My very special

thanks go to Mr. Hans-Peter Thür, the CEO of Birkhäuser Publishing for his constant support and encouragement to continue with the editorship of PDR.

Basel, September 1998

Dr. E. Jucker